Related Experiment Videos
The toxicity of daily inhaled amphotericin B
J Gryn1, J Goldberg, E Johnson
1Department of Medicine, Robert Wood Johnson School of Medicine/Cooper University Medical Center, Camden, New Jersey.
Abstract:
Inhaled amphotericin was administered to 29 patients with prolonged neutropenia and toxicity was analyzed. Treatment consisted of 30 mg of amphotericin B administered by nebulizer once daily via either a hand-held nebulizer or face mask. The mean duration of treatment was 16 days. Toxicity was minimal and patient had significant toxic reaction to the inhaled medication. This study documents that nebulized amphotericin B has less than 10% incidence of severe toxicity with 95% confidence level. Guidelines for future trials and use are suggested.
Insights
Nebulized amphotericin B offers a low toxicity alternative for patients with prolonged neutropenia. This inhaled antifungal treatment demonstrated minimal severe adverse events in a recent clinical study.
Area of Science:
- Infectious Diseases
- Pulmonology
- Pharmacology
Background:
- Prolonged neutropenia increases susceptibility to invasive fungal infections.
- Conventional amphotericin B formulations are associated with significant systemic toxicity.
- Inhaled antifungal therapy is being explored as a less toxic alternative.
Purpose of the Study:
- To evaluate the safety and toxicity profile of inhaled amphotericin B in patients with prolonged neutropenia.
- To determine the incidence of severe adverse events associated with nebulized amphotericin B administration.
Main Methods:
- Twenty-nine patients with prolonged neutropenia received inhaled amphotericin B (30 mg daily) via nebulizer.
- Treatment duration averaged 16 days.
- Toxicity was systematically monitored and analyzed.
Main Results:
- Inhaled amphotericin B was associated with minimal toxicity.
- The incidence of severe toxic reactions to the inhaled medication was low.
- Severe toxicity occurred in less than 10% of patients (95% confidence level).
Conclusions:
- Nebulized amphotericin B is a well-tolerated treatment option for patients experiencing prolonged neutropenia.
- This administration route significantly reduces the risk of severe toxicity compared to conventional methods.
- Further clinical trials and guidelines for use are recommended.